Biophytis (ALBPS.PA) Trading Update
Date: 23 October 2026Time of Reference: 02:03 PM Central Europe
Stock Performance
- Current price: EUR 0.04
- 24‑hour change: +1.19 %
- Last 24‑hour volume: EUR 485.2 k
- Last 24‑hour traded volume (shares): 12 M
- Market capitalization: EUR 12.7 M
- Shares outstanding: 42.1 M
- Simple moving average (200 days): EUR 0.04
- 52‑week high: EUR 0.16 (17 August 2026)
- 52‑week low: EUR 0.00 (31 July 2026)
- Month‑end performance: −28.12 % compared with the previous month.
Peer Comparison (last 24 hours)
| Stock | 24‑hour change | Current price | Market cap |
|---|---|---|---|
| Vogo Saca (ALVGO.PA) | 0 % | EUR 1.66 | EUR 13.5 M |
| Obiz (ALBIZ.PA) | −1.54 % | EUR 2.56 | EUR 15.0 M |
| Biosynex (ALBIO.PA) | −4.39 % | EUR 0.80 | EUR 14.7 M |
| Orege (OREGE.PA) | +0.75 % | EUR 0.28 | EUR 14.7 M |
| Stradim‑espace Finances (ALSAS.PA) | +10.23 % | EUR 3.88 | EUR 14.5 M |
| – | – | – | – |
| Price‑to‑earnings ratio (Stradim‑espace Finances) | – | – | 7.85 |
Company Overview
Biophytis SA is a Paris‑based biotechnology firm, founded in 2006, focused on developing therapies for age‑related degenerative conditions. Current clinical activities include:
- Sarcopenia trial – therapeutic intervention for muscle wasting in older adults.
- Duchenne muscular dystrophy trial – evaluation of novel treatment modalities.
- Macuneos – Phase I/IIa study targeting age‑related macular degeneration and genetic retinopathy.
The company’s products and pipeline are detailed on its website, www.biophytis.com , and shares are listed on NYSE Euronext Paris.
All figures are current as of the market close on 23 October 2026 and are reported in euros.
